Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12677
Title: Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies.
Authors: Dingjan, Tamir;Spendlove, Ian;Durrant, Lindy G;Scott, Andrew M;Yuriev, Elizabeth;Ramsland, Paul A
Affiliation: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
Academic Department of Clinical Oncology, Division of Cancer and Stem cells, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom.
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. Electronic address: elizabeth.yuriev@monash.edu.
Centre for Biomedical Research, Burnet Institute, Melbourne, VIC 3004, Australia; Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia; Department of Surgery Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia; School of Biomedical Sciences, CHIRI Biosciences, Curtin University, Perth, WA 6845, Australia. Electronic address: pramsland@burnet.edu.au.
Issue Date: 7-Mar-2015
Citation: Molecular Immunology 2015; 67(2 Pt A): 75-88
Abstract: Monoclonal antibodies represent the most successful class of biopharmaceuticals for the treatment of cancer. Mechanisms of action of therapeutic antibodies are very diverse and reflect their ability to engage in antibody-dependent effector mechanisms, internalize to deliver cytotoxic payloads, and display direct effects on cells by lysis or by modulating the biological pathways of their target antigens. Importantly, one of the universal changes in cancer is glycosylation and carbohydrate-binding antibodies can be produced to selectively recognize tumor cells over normal tissues. A promising group of cell surface antibody targets consists of carbohydrates presented as glycolipids or glycoproteins. In this review, we outline the basic principles of antibody-based targeting of carbohydrate antigens in cancer. We also present a detailed structural view of antibody recognition and the conformational properties of a series of related tissue-blood group (Lewis) carbohydrates that are being pursued as potential targets of cancer immunotherapy.
Internal ID Number: 25757815
URI: http://ahro.austin.org.au/austinjspui/handle/1/12677
DOI: 10.1016/j.molimm.2015.02.028
URL: http://www.ncbi.nlm.nih.gov/pubmed/25757815
Type: Journal Article
Subjects: Antibody tumor targeting
Blood group carbohydrates
Cancer immunotherapy
Carbohydrate conformations
Carbohydrate recognition
Protein–carbohydrate interactions
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.